• Home
  • Outline
  • Members
  • Report
  • Contact

Outline

Outline

Mission: to “realize the application of human iPSC-derived cardiomyocytes, hepatocytes and neurons for drug safety evaluations by both technological advancement and including policy recommendations.”

Organizational structure

Organizational structure

An Executive Committee

and ten others
Consortium Leader Norimasa Miyamoto, Ph.D.
(Eisai Co., Ltd.)
Cardiomyocyte Team Leader Kiyosi Takasuna, Ph.D.
(Daiichisankyo Co., Ltd.)
Hepatocyte Team Leader Tomoaki Inoue, Ph.D.
(Chugai Pharmaceutical Co., Ltd.)
Neuron Team Leader Takafumi Shirakawa, Ph.D.
(Astellas Pharma Inc.)
Cell Characterization Team Leader Tadahiro Shinozawa, Ph.D.
(Takeda Pharmaceutical Co., Ltd.)
3D Model Team Leader Tesuro Araki, Ph., D.
(Asahi Kasei Pharma Corp.)

» Outline (Jul.8, 2013 - Mar. 31, 2016)

  • Japan iPS Cardiac Safety Assessment (JiCSA)
  • Introduction of UK Scotland life science
Page Top